The CheckMate‐142 study showed durable responses following treatment with nivolumab, an anti‐PD‐1 antibody, alone and in combination with ipilimumab, an anti‐CTLA‐4 antibody, in a subgroup of stage IV CRC patients with MSI‐H tumors.7 The gene discussed is CTLA4; the disease is colorectal carcinoma.